Investigating the efficacy of insert nanofibers containing Vancomycin and Amikacin in patients with infectious keratitis
Not Applicable
Recruiting
- Conditions
- Corneal ulcer.Corneal ulcerH16.0
- Registration Number
- IRCT20130812014333N216
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Age above 18 years
Bacterial corneal ulcer with high clinical suspicion
Wound size greater than 2 mm
BCVA greater than 200/20 in the uninvolved eye
Exclusion Criteria
Patients with uncontrolled diabetes
Corneal perforation or its imminent
Symptoms of inflammation in both eyes
History of glaucoma shunt or filtering surgery
Pregnant or lactating women
History of corneal surgery due to refractive errors
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Vancomycin and Amikacin in treating infectious keratitis?
How do nanofiber drug delivery systems improve antibiotic efficacy in corneal ulcers compared to traditional methods?
What biomarkers are associated with response to Vancomycin and Amikacin in corneal infections caused by Gram-positive and Gram-negative bacteria?
What are the potential adverse events of using nanofiber inserts with Vancomycin and Amikacin in ophthalmic treatments?
Are there any alternative antibiotic combinations or delivery methods being studied for corneal ulcers by Kermanshah University of Medical Sciences?